These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Dialysis facility ownership and epoetin dosing in hemodialysis patients: an overview. Weiner DE; Levey AS Am J Kidney Dis; 2007 Sep; 50(3):349-53. PubMed ID: 17720511 [No Abstract] [Full Text] [Related]
24. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia. Binkley LS Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169 [No Abstract] [Full Text] [Related]
25. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective. Lazarus JM; Hakim RM Am J Kidney Dis; 2007 Sep; 50(3):366-70. PubMed ID: 17720515 [No Abstract] [Full Text] [Related]
26. Epoetin alfa: focus on maintaining a higher, stable, Hct. Case study of the anemic patient. Cohen JA; Brattich M ANNA J; 1997 Oct; 24(5):574-80; quiz 581. PubMed ID: 9392740 [TBL] [Abstract][Full Text] [Related]
27. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a view from Europe. Macdougall IC Am J Kidney Dis; 2007 Sep; 50(3):358-61. PubMed ID: 17720513 [No Abstract] [Full Text] [Related]
28. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspective. Cohen JT; Neumann PJ Am J Kidney Dis; 2007 Sep; 50(3):362-5. PubMed ID: 17720514 [No Abstract] [Full Text] [Related]
29. Anemia management in pediatric dialysis patients. Case study of the anemic patient. Currier H ANNA J; 1999 Jun; 26(3):349-52. PubMed ID: 10633609 [TBL] [Abstract][Full Text] [Related]
30. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828 [TBL] [Abstract][Full Text] [Related]
31. Should all patients with chronic kidney disease receive an EPO-type drug? Berns JS Cleve Clin J Med; 2006 Mar; 73(3):298-300. PubMed ID: 16548453 [No Abstract] [Full Text] [Related]
35. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion. Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770 [TBL] [Abstract][Full Text] [Related]
36. Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment. Siems W; Carluccio F; Radenkovic S; Grune T; Hampl H Kidney Blood Press Res; 2005; 28(5-6):295-301. PubMed ID: 16534224 [TBL] [Abstract][Full Text] [Related]
37. New oversight put in place for physicians giving anemia drugs to patients with cancer. Mitka M JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885 [No Abstract] [Full Text] [Related]
38. A successful anaemia management algorithm that achieves and maintains optimum haemoglobin status. Benton S J Ren Care; 2008 Jun; 34(2):54-8. PubMed ID: 18498568 [TBL] [Abstract][Full Text] [Related]
39. Anemia: What can we learn from a secondary analysis of CHOIR? Hörl WH Nat Rev Nephrol; 2010 May; 6(5):251-2. PubMed ID: 20424625 [No Abstract] [Full Text] [Related]
40. Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial. Mehta KS; Sinha SD; Vamsi B; Reddy B; Naidu NR; Thakur PA; Sreenivasa C; Reddy VPR; Pandey R; Durugkar S J Assoc Physicians India; 2019 Jan; 67(1):62-66. PubMed ID: 30935177 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]